热疗联合同步放化疗对中晚期宫颈癌的临床疗效及血清热休克蛋白90α表达的影响  

Clinical efficacy of hyperthermia combined with concurrent chemoradiotherapy on advanced cervical cancer and influence of serum heat-shock protein 90α expression

作　　者：肖鑫[1] 盛晓安 施险峰 董娟娟[1] 许娟[1] 汪超[1] XIAO Xin;SHENG Xiao-an;SHI Xian-feng;DONG Juan-juan;XU Juan;WANG Chao(Department of Oncology,Chaohu Hospital of Anhui Medical University,Hefei,Anhui 238000,China)

机构地区：[1]安徽医科大学附属巢湖医院肿瘤内科,安徽合肥238000

出　　处：《中华全科医学》2022年第7期1109-1112,共4页Chinese Journal of General Practice

基　　金：安徽省卫生健康委科研项目(AHWJ2021b018)。

摘　　要：目的探讨热疗联合同步放化疗对中晚期宫颈癌患者的临床疗效,宫颈癌患者治疗前后血清中热休克蛋白90α(HSP90α)表达的变化及预测治疗效果的临床价值。方法选取2017年1月—2019年6月安徽医科大学附属巢湖医院收治的80例中晚期宫颈癌患者作为研究对象,将其中单纯同步放化疗治疗的40例患者纳入对照组,在对照组的基础上联合热疗的40例患者纳入研究组,比较2组近期疗效及毒性反应,并检测宫颈癌患者治疗前后血清HSP90α指标的变化。结果研究组总有效率为87.5%,明显优于对照组的65.0%,2组比较差异有统计学意义(P<0.05);研究组2年生存率明显高于对照组,差异有统计学意义(P<0.05);2组不良反应发生情况比较差异无统计学意义(均P>0.05);宫颈癌患者治疗前后HSP90α变化比较,差异有统计学意义(P<0.05)。结论热疗联合同步放化疗明显改善了患者近期疗效,没有明显增加治疗副反应,并且提高患者2年的总生存率,治疗有效的中晚期宫颈癌患者血清HSP90α表达水平出现明显下降,疗效较好,值得推广。Objective To investigate the clinical efficacy of hyperthermia combined with concurrent chemoradiotherapy in patients with advanced cervical and endocervical cancer(CESC),the changes in serum heat-shock protein 90α(HSP90α)expression before and after treatment and the value of predicting the therapeutic effect.Methods A total of 80 patients with advanced CESC who were admitted to Chaohu Hospital Affiliated to Anhui Medical University from January 2017 to June 2019 were selected as the research subjects.Amongst then,40 patients who were treated with simple concurrent chemoradiotherapy were included in the control group.On the basis of the control group,40 patients with combined hyperthermia were included in the study group.The short-term efficacy and toxicity between the two groups were compared and the changes in serum HSP90α indices in patients before and after treatment were detected.Results The total effective rate of the study group was 87.5%,which was significantly better than that of the control group(65.0%),and the difference was statistically significant(P<0.05).The 2-year survival rate of the study group was significantly higher than that of the control group(P<0.05).By contrast,no significant difference was found in the incidence of adverse reactions between the two groups(all P>0.05).In patients,the difference in the comparison of HSP90α changes before and after treatment was statistically significant(P<0.05).Conclusion Hyperthermia combined with concurrent chemoradiotherapy could significantly improve the short-term curative effect in patients without significantly increasing the side effects of treatment and improve their 2-year overall survival rate.The expression of serum HSP90α decreased significantly in patients with middle-advanced CESC who have been effectively treated and the curative effect is good,hence worthy of promotion.

关 键 词：热疗 放疗 化疗 宫颈癌 热休克蛋白90Α 疗效 

分 类 号：R737.33[医药卫生—肿瘤] R730.5[医药卫生—临床医学]